CompletedNot Applicable

Parathyroidectomy in Endstage Renal Disease

Hong Kong122 participantsStarted 2007-03

Plain-language summary

To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease patients on maintenance dialysis.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Endstage renal disease patients receiving either long-term hemodialysis or peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels \> 500pg/ml on two or more occasions. * Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound imaging or radioisotope scan. * Patients who provide informed consent for the study. Exclusion Criteria: * Patients with significant background valvular heart disease * Patients who are unfit for general anaesthesia * Patients with acute myocardial infarction within recent two months * Patients with poor general condition * Patients with plans for living related kidney transplant within 1 year * Patients with previous history of parathyroidectomy * Patients with calciphylaxis * Patients with underlying active malignancy * Patients with contraindication for MRI

What they're measuring

Change in vascular and valvular calcium scores

Timeframe: 12 months

Trial details

NCT IDNCT00745719

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-09

View on ClinicalTrials.gov More Endstage Renal Disease trials